Successful Long-term Application of Highly Purified Natural Interferon-alpha (Multiferon®) after Preceding Interferon Approaches in a Chronic Hepatitis C Patient with Thrombocytopenia

References

• Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666–72.
   PubMed Web of Science ®Google Scholar
• Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, et al. Hepatitis Interventional Therapy Group. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34: 395–403.
   Google Scholar
• Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiff- man M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958–65.
   Google Scholar
• Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975–82.
   Google Scholar
• Colloredo G, Roffi L, Bellati G. Breakthrough during interferon therapy for chronic hepatitis C. Overview on the diagnosis, possible aetiology and recommendations for management. Ital J Gastroenterol Hepatol 1998; 30: 333–7.
   Google Scholar
• Toccaceli F, Rosati S, Scuderi M, Iacomi F, Picconi R, Laghi V. Leukocyte and platelet reduction by some interferon types during viral hepatitis treatment. Hepatogastroenterology 1998; 45: 1748–52.
   PubMed Web of Science ®Google Scholar
• Mazzoran L, Grassi G, Giacca M, Gerini U, Baracetti S, Fanni- Canelles M, et al. Pilot study on the safety and efficacy of intravenous natural beta-interferon therapy in patients with chronic hepatitis C unresponsive to alpha-interferon. Ital J Gastroenterol Hepatol 1997; 29: 338–42.
   Google Scholar
• Roffi L, Mels GC, Antonelli G, Bellati G, Panizzuti F, Piperno A, et al. Breakthrough during recombinant interferon-alpha therapy in patients with chronic hepatitis C virus infection: prevalence, aetiology, and management. Hepatology 1995; 21: 645–9.
   PubMedGoogle Scholar
• Sanjo A, Satoi J, Ohnishi A, Maruno J, Fukata M, Suzuki N. Role of elevated platelet-associated immunoglobulin G and hypersplenism in thrombocytopenia of chronic liver disease. J Gastroenterol Hepatol 2003; 18: 638–44.
   PubMed Web of Science ®Google Scholar
• Colombatto P, Oliveri F, Leandro G, Baldi M, Capalbo M, Rocca G, et al. Platelet and white blood cell counts during therapy with different types of alpha-interferon in patients with chronic viral hepatitis. Investigators of the Alpha Interferon Study Group of Piemonte, Italy. Ital J Gastroenterol Hepatol 1997; 29: 441–7.
   PubMedGoogle Scholar
• Benci A, Caremani M, Tacconi D. Thrombocytopenia in patients with HCV-positive chronic hepatitis: efficacy of leucocyte interferon-alpha treatment. Int J Clin Pract 2003; 57: 17–9.
   Google Scholar
• Weiland O, Chen M, Lindh G, Mattsson L, Schvarcz R, Sonnerborg A, et al. Efficacy of human leukocyte alphainterferon treatment for chronic hepatitis C virus infection. Scan J Infect Dis 1995; 27: 319–24.
   Web of Science ®Google Scholar
• Montalto G, Soresi M, Carroccio A, Anastasi G, Campagna P, Vasile F, et al. Comparative responses to 3 different types of interferon-alpha in patients with chronic hepatitis C. Curr Med Res Opin 1998; 14: 235–41.
   PubMed Web of Science ®Google Scholar
• Mazzoran L, Zorat F, Chemello L, Croce LS, Rigato I, Cavalletto L, et al. Human leucocyte interferon-alpha in the treatment of chronic hepatitis C. Dig Liver Dis 2001; 33: 34752.
   Google Scholar
• Gaeta GB, Virgilio D, Russo G, Stornaiuolo G, Nicolella U, Colella F, et al. Human leukocyte interferon-alpha in chronic hepatitis C resistant to recombinant or lymphoblastoid interferon-alpha: randomized controlled trial. J Viral Hepat 1997; 4: 209–14.
   PubMedGoogle Scholar
• Cagnoni C, Pancotti D, Carrara G. Management of patients with HCV infection poorly tolerant to recombinant interferonalpha. Hepatogastoenterology 2000; 47: 199–203.
   Google Scholar
• Berg T, Hopf U, Schuff-Werner P. Sustained remission of chronic hepatitis C after a change to human leukocyte interferon-alpha in a difficult-to-treat patient with breakthrough phenomenon associated with antibodies against recombinant interferon-alpha. Am J Gastroenterol 2001; 96: 612–4.
   Google Scholar
• Viscomi GC, Grimaldi M, Palazzini E, Silvestri S. Human leukocyte interferon-alpha: structure, pharmacology and therapeutic applications. Med Res Rev 1995; 15: 445–78.
   PubMedGoogle Scholar
• Chu CW, Hwang SJ, Luo JC, Lai CR, Tsay SH, Li CP, et al. Clinical, virological, and pathological significance of elevated serum alpha-fetoprotein levels in patients with chronic hepatitis C. J Clin Gastroenterol 2001; 32: 240–4.
   PubMed Web of Science ®Google Scholar
• Stein DF, Myaing M. Normalizaton of markedly elevated alpha-fetoprotein in a virological non-responder with HCV- related cirrhosis. Dig Dis Sci 2002; 47: 2686–90.
   PubMedGoogle Scholar
• Battacharya R, Shuhart MC. Hepatitis C and alcohol: interactions, outcomes, and implications. J Clin Gastroenterol 2003; 36: 242–52.
   PubMedGoogle Scholar
• Khan KN, Yatsuhashi H. Effect of alcohol consumption on the progression of hepatitis C virus infection and risk of hepatocellular carcinoma in Japanese patients. Alcohol 2000; 35: 286–95.
   Google Scholar
• Nishigucchi S, Shiomi S, Nakatani S, Takeda T, Fukuda K, Tamori A, et al. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet 2001; 357: 196–7.
   PubMedGoogle Scholar
• Shigeno M, Nakao K, Ichikawa T, Suzuki K, Kawakami A, Abiru S, et al. Interferon-alpha sensitizes human hepatoma cells to TRIAL-induced apoptosis through DR5 up-regulation and NF-kappa B inactivation. Oncogene 2003; 22: 1653–62.
   PubMed Web of Science ®Google Scholar
• Shiratori Y, Shiina S, Teratani T, Imamura M, Obi S, Sato S, et al. Interferon therapy after tumour ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 2003; 138: 200–306.
   Google Scholar